ReproNovo raises €57 million with Ysios Capital's participation and opens in Barcelona

BarcelonaThe Swiss-based biotechnology company ReproNovo, specializing in the development of reproductive health treatments, has closed a $65 million financing round, equivalent to approximately €57.4 million at the current exchange rate, and has announced the opening of a subsidiary in Barcelona. In fact, the Catalan asset manager Ysios Capital participated in the round, led by Jeito Capital. Other investors included AXA IM Alts, M Ventures, and Alsa Ventures.

In a statement, Ysios Capital explained this Wednesday that the amount raised in the round will be used to finance innovative reproductive health therapies. ReproNovo is a biotechnology company specializing in the development of pioneering treatments for both male and female infertility. The Swiss company has announced that it has established a subsidiary in Barcelona to strengthen its clinical activity in the Catalan capital: "The city has established itself as a European hub for reproductive health, both for the quality of its specialized clinics and for its ecosystem of innovation and talent in biomedical research," it said.

ReproNovo is the sixteenth and final investment from Ysios Capital's third fund, Ysios BioFund III, and the first in the reproductive health sector. With this round of funding, Ysios Capital partner Guillem Laporta has joined ReproNovo's board of directors, along with representatives from Jeito Capital, AXA IM Alts, and M Ventures.